<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="32e1b12d-ed8c-33a3-e063-6294a90a3109"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BYQLOVI 
 <sup>®</sup>safely and effectively. See full prescribing information for BYQLOVI.
 <br/>
      <br/>
BYQLOVI,
 <br/>
for topical ophthalmic use
 <br/>
Initial U.S. Approval: 1985
</title>
   <effectiveTime value="20250416"/>
   <setId root="7687c980-7006-4222-80b9-c32773772d3e"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="081032969"/>
            <name>Eyenovia, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="32e1f1fa-4529-8631-e063-6294a90ad637"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="81046-0319" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CLOBETASOL PROPIONATE</name>
                        <formCode code="C60995" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>CLOBETASOL PROPIONATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H1109Z9J4N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROGENATED SOYBEAN LECITHIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="TUF2IVW3M2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLOXAMER 407</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z944H5SN0H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RS7A450LGA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS TRISODIUM CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="779619577M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CLOBETASOL PROPIONATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="ADN79D536H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CLOBETASOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="81046-0319-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240325"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218158" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240325"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="32e1b12d-ed8d-33a3-e063-6294a90a3109"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>BYQLOVI is indicated for the treatment of post-operative inflammation and pain following ocular surgery.</paragraph>
               </text>
               <effectiveTime value="20250416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="32e1b12d-ed8e-33a3-e063-6294a90a3109"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Instill one drop of BYQLOVI into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>Wash hands well before each use. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="32e1b12d-ed8f-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>Instill one drop of BYQLOVI into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="32e1b12d-ed90-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration Instructions</title>
                     <text>
                        <paragraph>Wash hands well before each use.</paragraph>
                        <paragraph>If using other eye drops in addition to BYQLOVI, wait at least 5 minutes between instillation of BYQLOVI and other eye drops.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="32e1b12d-ed91-33a3-e063-6294a90a3109"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ophthalmic suspension containing clobetasol propionate 0.05% (0.5 mg/mL).</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic suspension containing clobetasol propionate 0.05%. (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="32e1b12d-ed92-33a3-e063-6294a90a3109"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="32e1b12d-ed93-33a3-e063-6294a90a3109"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Intraocular Pressure (IOP) Increase</content>: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Cataracts</content>: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Delayed Healing</content>: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Corneal and Scleral Melting</content>: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. (
  
     <linkHtml href="#S5.4">5.4</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Bacterial Infections</content>: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. (
  
     <linkHtml href="#S5.5">5.5</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Viral Infections</content>: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). (
  
     <linkHtml href="#S5.6">5.6</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Fungal Infections</content>: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. (
  
     <linkHtml href="#S5.7">5.7</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="32e1b12d-ed94-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Intraocular Pressure (IOP) Increase</title>
                     <text>
                        <paragraph>Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If BYQLOVI is used for 10 days or longer, IOP should be monitored.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="32e1b12d-ed95-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Cataracts</title>
                     <text>
                        <paragraph>Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="32e1b12d-ed96-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Delayed Healing</title>
                     <text>
                        <paragraph>The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="32e1b12d-ed97-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Corneal and Scleral Melting</title>
                     <text>
                        <paragraph>In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="32e1b12d-ed98-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Bacterial Infections</title>
                     <text>
                        <paragraph>Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="32e1b12d-ed99-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Viral Infections</title>
                     <text>
                        <paragraph>Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="32e1b12d-ed9a-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Fungal Infections</title>
                     <text>
                        <paragraph>Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal culture should be taken when appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="32e1b12d-ed9b-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Risk of Contamination</title>
                     <text>
                        <paragraph>Do not allow the dropper tip to touch any surface, as this may contaminate the ophthalmic suspension.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="32e1b12d-ed9c-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Contact Lens Wear</title>
                     <text>
                        <paragraph>BYQLOVI should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of BYQLOVI. The preservative in BYQLOVI may be absorbed by soft contact lenses. Lenses may be reinserted after 15 minutes following administration of BYQLOVI.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="32e1b12d-ed9d-33a3-e063-6294a90a3109"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious reactions are found elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Intraocular Pressure (IOP) Increase
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Posterior Subcapsular Cataract Formation
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Delayed Healing
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Corneal and Scleral Melting
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                     <item>Bacterial Infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
  
   </content>
                     </item>
                     <item>Viral Infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]
  
   </content>
                     </item>
                     <item>Fungal Infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure (
 
    <linkHtml href="#S6.1">6.1</linkHtml>).

   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Eyenovia, Inc. at 1-833-393-6684 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="32e1b12d-ed9e-33a3-e063-6294a90a3109"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="32e1b12d-ed9f-33a3-e063-6294a90a3109"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250416"/>
               <component>
                  <section ID="S8.1">
                     <id root="32e1b12d-eda0-33a3-e063-6294a90a3109"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="32e1b12d-eda1-33a3-e063-6294a90a3109"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate and well-controlled clinical studies of BYQLOVI administration in pregnant women to inform drug-associated risks. Plasma concentrations of clobetasol propionate were minimal following topical ophthalmic administration of BYQLOVI 
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>. However, corticosteroids, including clobetasol propionate have been shown to be teratogenic and fetotoxic in laboratory animals when administered systemically at relatively low dosage levels
 
  <content styleCode="italics">(see
  
   <linkHtml href="#data">Data</linkHtml>)
 
  </content>.

 </paragraph>
                              <paragraph>BYQLOVI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                              <paragraph>In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="32e1b12d-eda2-33a3-e063-6294a90a3109"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                           <component>
                              <section>
                                 <id root="32e1b12d-eda3-33a3-e063-6294a90a3109"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In embryofetal development studies in mice, clobetasol propionate was fetotoxic at the highest subcutaneous dose tested (1 mg/kg) and teratogenic at all subcutaneous dose levels tested down to 0.03 mg/kg. Abnormalities observed included cleft palate and skeletal abnormalities. These doses are approximately 98 times and 3 times, respectively, the recommended human ophthalmic dose of BYQLOVI, estimated based on body surface area and assuming 100% systemic absorption.</paragraph>
                                    <paragraph>In embryofetal development studies in rabbits, clobetasol propionate was teratogenic at subcutaneous doses of 3 and 10 µg/kg. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. These doses are approximately 1.2 times and 3.9 times, respectively, the recommended human ophthalmic dose of BYQLOVI, estimated based on body surface area and assuming 100% systemic absorption.</paragraph>
                                 </text>
                                 <effectiveTime value="20250416"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="32e1b12d-eda4-33a3-e063-6294a90a3109"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="32e1b12d-eda5-33a3-e063-6294a90a3109"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of clobetasol propionate in human milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                              <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. However, systemic levels of clobetasol propionate following topical ocular administration are minimal
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>],
 
  </content>and it is not known whether measurable levels of clobetasol propionate would be present in maternal milk following topical ocular administration.

 </paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BYQLOVI, and any potential adverse effects on the breastfed infant from BYQLOVI.</paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="32e1b12d-eda6-33a3-e063-6294a90a3109"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of BYQLOVI in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="32e1b12d-eda7-33a3-e063-6294a90a3109"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness of BYQLOVI have been observed between patients 65 years of age and older and younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="32e1b12d-eda8-33a3-e063-6294a90a3109"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% contains the active compound clobetasol propionate, a synthetic corticosteroid, that has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.</paragraph>
                  <paragraph>Chemically, clobetasol propionate is 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate and it has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Clobetasol propionate has the empirical formula C
 
  <sub>25</sub>H
 
  <sub>32</sub>CIFO
 
  <sub>5</sub>and a molecular weight of 467.

 </paragraph>
                  <paragraph>BYQLOVI contains a sterile, anti-inflammatory corticosteroid for topical ophthalmic use.</paragraph>
                  <paragraph>Each mL of BYQLOVI contains:</paragraph>
                  <paragraph>ACTIVE: clobetasol propionate 0.5 mg (0.05%)</paragraph>
                  <paragraph>INACTIVES: sodium chloride, hydrogenated soybean lecithin, citric acid, glycerin, poloxamer 407, polyvinyl alcohol, boric acid, edetate disodium dihydrate, methylcellulose, trisodium citrate, and water for injection</paragraph>
                  <paragraph>PRESERVATIVE: benzalkonium chloride 0.0036%.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="32e1b12d-eda9-33a3-e063-6294a90a3109"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="S12.1">
                     <id root="32e1b12d-edaa-33a3-e063-6294a90a3109"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A
 
  <sub>2</sub>inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A
 
  <sub>2</sub>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="32e1b12d-edab-33a3-e063-6294a90a3109"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In patients treated with BYQLOVI twice daily for 21 days, the mean (SD) changes from baseline in cortisol concentrations, -18.1 (126.2) nmol/L and +5.1 (129.8) nmol/L for the BYQLOVI and matching vehicle arms, respectively, were not statistically significant, considering the variability observed in the cortisol concentrations.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="32e1b12d-edac-33a3-e063-6294a90a3109"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>After the first and second (12 hours apart) ocular instillations of BYQLOVI in healthy adults (n=12), peak plasma clobetasol propionate concentrations (C
 
  <sub>max</sub>) were below the lower limit of quantitation (LLOQ, 0.04 ng/mL) in 13 out of 22 PK profiles and ranged from 0.040 to 0.182 ng/mL in the other 9 profiles. Time to peak concentration (T
 
  <sub>max</sub>) was observed between 0.5 - 1 hour post-dose. Clobetasol propionate concentrations declined to lower than LLOQ after 4 to 5 hours post-dose.

 </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="32e1b12d-edad-33a3-e063-6294a90a3109"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="S13.1">
                     <id root="32e1b12d-edae-33a3-e063-6294a90a3109"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250415"/>
                     <component>
                        <section>
                           <id root="32e1b12d-edaf-33a3-e063-6294a90a3109"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long-term animal studies have not been performed with BYQLOVI to evaluate the carcinogenic potential of clobetasol propionate.</paragraph>
                           </text>
                           <effectiveTime value="20250415"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="32e1b12d-edb0-33a3-e063-6294a90a3109"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Clobetasol propionate was not mutagenic in 3 different test systems: the Ames test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test.</paragraph>
                           </text>
                           <effectiveTime value="20240322"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="32e1b12d-edb1-33a3-e063-6294a90a3109"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Fertility studies in the rat following subcutaneous administration at dosage levels up to 50 µg/kg/day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. This dose is approximately 10 times the recommended human ophthalmic dose of BYQLOVI (0.83 μg/kg/day), estimated based on body surface area and assuming 100% systemic absorption. Note that systemic levels of clobetasol propionate following topical ocular administration are minimal
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250415"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="32e1b12d-edb2-33a3-e063-6294a90a3109"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Clinical efficacy was evaluated in 2 multi-center, randomized, double-masked, vehicle-controlled trials in which patients had ≥10 cells in the anterior chamber after cataract surgery were assigned to BYQLOVI 0.05% (N=366) or vehicle (N=382) (
 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT04739709">NCT04739709</linkHtml>(Study 1) and
 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT04810962">NCT04810962</linkHtml>(Study 2)). One drop of Clobetasol Propionate Ophthalmic Suspension 0.05% or vehicle was self-administered twice a day for 14 days, beginning on the day after surgery. Complete resolution of inflammation (an anterior chamber cell count of 0 maintained through Day 15 without rescue medication) and complete resolution of pain (a patient-reported pain grade of 0 maintained through Day 15 without rescue medication) were assessed at post-operative day (POD) 4, 8, and 15. (Study 1) and
 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT04810962">NCT04810962</linkHtml>(Study 2)). One drop of BYQLOVI 0.05% or vehicle was self-administered twice a day for 14 days, beginning on the day after surgery. Complete resolution of inflammation (an anterior chamber cell count of 0 maintained through Day 15 without rescue medication) and complete resolution of pain (a patient-reported pain grade of 0 maintained through Day 15 without rescue medication) were assessed at post-operative day (POD) 4, 8, and 15.

 </paragraph>
                  <paragraph>The co-primary efficacy endpoints were the proportion of subjects with Anterior Chamber Cell (ACC) count = 0 (ACC grade = 0) at POD8 maintained through POD15, and the proportion of subjects with Ocular Pain Grade = 0 at POD4 maintained through POD15. In the intent-to-treat analysis, both co-primary efficacy endpoints were statistically significantly better in BYQLOVI 0.05%-treated patients compared to vehicle-treated patients (p&lt;0.01). The clinical trial efficacy results from both studies are provided below.</paragraph>
                  <table width="80%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <thead>
                        <tr styleCode="First Last">
                           <th colspan="2" align="left">Figure 1: Percent of Patients with Anterior Chamber Cell Count = 0 at Post-Operative Days 8 and 15</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="First Last">
                           <td align="left">
                              <paragraph>
                                 <renderMultiMedia referencedObject="Lb4cab5fd-dc33-458a-89e7-71b6d110cd12"/>
                              </paragraph>
                           </td>
                           <td align="left">
                              <paragraph>
                                 <renderMultiMedia referencedObject="La628d8f9-1e6e-4b12-9e0b-b049bae3fc29"/>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="60%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <thead>
                        <tr styleCode="First Last">
                           <th colspan="2" align="left">Figure 2: Percent of Patients with Complete Resolution of Pain at Post-Operative Days 4, 8, and 15</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="First Last">
                           <td align="left">
                              <paragraph>
                                 <renderMultiMedia referencedObject="Lff4988bf-a0b5-4f37-be74-e6a4ed234a40"/>
                              </paragraph>
                           </td>
                           <td align="left">
                              <paragraph>
                                 <renderMultiMedia referencedObject="L0081119d-be70-4715-b7c2-8ab4cee9de3f"/>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250416"/>
               <component>
                  <observationMedia ID="Lb4cab5fd-dc33-458a-89e7-71b6d110cd12">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="La628d8f9-1e6e-4b12-9e0b-b049bae3fc29">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lff4988bf-a0b5-4f37-be74-e6a4ed234a40">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L0081119d-be70-4715-b7c2-8ab4cee9de3f">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="32e1b12d-edb3-33a3-e063-6294a90a3109"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250416"/>
               <component>
                  <section ID="S16.1">
                     <id root="32e1b12d-edb4-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% (0.5 mg/mL) is a sterile ophthalmic suspension. It is supplied in a multi-dose white low-density polyethylene plastic 5 mL eye-dropper bottle with a low-density polyethylene white tip and a high-density polyethylene pink cap with a tamper-proof ring at the bottom of the cap.</paragraph>
                        <paragraph>3.5 mL in a 5 mL bottle (NDC 81046-0319-1)</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="32e1b12d-edb5-33a3-e063-6294a90a3109"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Do not use if tamper-evident ring seal is broken.</item>
                           <item>Keep the bottle tightly closed with the pink cap when not in use.</item>
                        </list>
                        <paragraph>Store upright at 15°C to 25°C (59°F to 77°F). Do not freeze. After opening, BYQLOVI can be used until the expiration date on the bottle.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="32e1b12d-edb6-33a3-e063-6294a90a3109"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250415"/>
               <component>
                  <section>
                     <id root="32e1b12d-edb7-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration with Other Eye Drops</content>
                        </paragraph>
                        <paragraph>Advise patients to wait at least 5 minutes between instillation of BYQLOVI and other eye drops if using other eye drops in addition to BYQLOVI.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32e1b12d-edb8-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of Contamination</content>
                        </paragraph>
                        <paragraph>Advise patients to wash their hands well before each use. Advise patients not to allow the dropper tip to touch any surface, as this may contaminate the ophthalmic suspension.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32e1b12d-edb9-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">When to Seek Physician Advice</content>
                        </paragraph>
                        <paragraph>Advise patients to consult a physician if pain develops; or if redness, itching, or inflammation becomes aggravated.</paragraph>
                     </text>
                     <effectiveTime value="20240322"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32e1b12d-edba-33a3-e063-6294a90a3109"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contact Lens Wear</content>
                        </paragraph>
                        <paragraph>Advise patients that the preservative in BYQLOVI may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of BYQLOVI and may be reinserted after 15 minutes following administration.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32e1b12d-edbb-33a3-e063-6294a90a3109"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by: 
  <br/>  Eyenovia, Inc. 
  <br/>  295 Madison Avenue, Suite 2400 
  <br/>  New York, NY 10017
 </paragraph>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section>
               <id root="32e1b12d-edbc-33a3-e063-6294a90a3109"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 3.5 mL Bottle and Carton Labels</title>
               <text>
                  <paragraph>NDC #: 81046-0319-1</paragraph>
                  <paragraph>BYQLOVI</paragraph>
                  <paragraph>(clobetasol propionate</paragraph>
                  <paragraph>ophthalmic suspension)</paragraph>
                  <paragraph>0.05%</paragraph>
                  <paragraph>FOR TOPICAL 
  <br/>  APPLICATION IN THE EYE
 </paragraph>
                  <paragraph>Sterile 
  <br/>  Rx only
 </paragraph>
                  <paragraph>3.5 mL</paragraph>
                  <paragraph>eyenovia</paragraph>
                  <paragraph/>
                  <paragraph>Bottle Label</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="L211a1d50-61b1-4410-865f-d55f25e2cc15"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Carton Label</paragraph>
                  <renderMultiMedia referencedObject="L10a2b717-93f5-4707-8539-9787b022f79e"/>
               </text>
               <effectiveTime value="20250416"/>
               <component>
                  <observationMedia ID="L211a1d50-61b1-4410-865f-d55f25e2cc15">
                     <text>PRINCIPAL DISPLAY PANEL - 3.5 mL Bottle Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L10a2b717-93f5-4707-8539-9787b022f79e">
                     <text>PRINCIPAL DISPLAY PANEL - 3.5 mL Bottle Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clobetasol-06-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>